University of Minnesota Designated Regional Treatment Center for COVID-19 Launching Three Clinical Trials

University of Minnesota Designated Regional Treatment Center for COVID-19 Launching Three Clinical Trials

The University of Minnesota Medical School commenced a study to test remdesivir, the experimental drug originally developed for Ebola, to determine if it can be used on those hospitalized due to COVID-19. The university has been designated by the federal government as a regional treatment center for the COVID-19 test—covering Minnesota, Michigan, and Illinois.

The Wall Street Journal reported on Friday that the drug appeared to positively affect a small group of Americans who contracted the coronavirus aboard a cruise ship and were treated in Japan. Although not effective in treating Ebola, thus far, none of the 14 cruise ship passengers has died reports the Star Tribune, even though many were reported critically ill.

Ongoing Clinical Trials

As recently reported by TrialSite News, of the at least 88 ongoing clinical trials worldwide, Remdesivir is involved with at least five of these studies in America and China. The Star Tribune reported that Gilead spokesman Chris Ridley confirmed the Remdesivir trials via email on Friday.

University of Minnesota Regional Treatment Center

The university has been designed by the federal government...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee